NOXXON Pharma AG, developer of a mirror-image oligonucleotide known as Spiegelmer, has appointed Joachim Kempeni as chief medical officer (CMO) and a member of its management board. In his role as CMO, Dr Kempeni will be responsible for the clinical development of NOXXON’s lead drug candidates for the treatment of renal inflammation and diabetic retinopathy.
Dr Kempeni joined NOXXON from Astellas Pharma, where he was vice president of research and development for Europe. NOXXON Pharma is located in Berlin, Germany.
Source:
Noxxon Pharma press release, 1 October 2007
Copyright 2007 Evernow Publishing Ltd